Close
Home Life sciences

Life sciences

We have one of the most renowned life sciences practices in the UK. We help leading companies to commercialise their technology and scientific discoveries. Our life sciences practice helps companies bring more innovative drugs, therapies and devices to the market, enabling people to live longer and healthier lives.

We have solid experience in helping companies develop, test and commercialise pharmaceutical products through their entire life cycle. We help companies invest in and commercialise technology and scientific discoveries.

Our clients include pharmaceuticals, biotech, medical devices and healthcare companies, whom we advise on agreements covering confidentiality, research collaboration, manufacturing and distribution; as well as assisting them with ethics and compliance issues, investment and employee share option schemes.

For further help or information

Get in touch

Withers tech

Tech law firm JAG Shaw Baker has joined us to create a unique legal offering that meets the needs of entrepreneurs, investors and technology companies across the world.

Find out more

26 October 2017 - Blog

Five tips to prepare your life sciences organisation for the GDPR

Read More

Recognition

Meet the team

Protecting your IP

Data protection

IP infringements

Managing your people

Protecting your intellectual property

Managing people

Defending your brand

Professional discipline and regulatory

Expanding internationally

Track record

Advised Mologic Limited, a UK biotech on a collaboration agreement with another UK biotech for peptide selection.

Advised the client on the financial element of the deal including clinical development milestones, first product sale in US, EU and Japan and net commercialisation revenues

Acting as General Counsel for Bioven

Acting as General Counsel for Bioven, an international biotech company on all legal matters worldwide dealing with high value negotiations and contracts with third parties including pre-clinical trials and Phase III clinical trials.

Advising Omega Funds on their equity investment into BioSilta Holdings Ltd

Advising Omega Funds on their equity investment into BioSilta Holdings Ltd, a company that develops advanced microbial growth systems, involving a UK flip from a Finnish company and subsequent equity investment.

Acted for the founders of Morphogen-IX

Acted for the founders of Morphogen-IX, in respect of its spin out from Cambridge University and Series A funding from Medicxi Ventures.

Acted for Medovate Limited

Acted for Medovate Limited, in respect of the set up and venture capital funding of this company established to enable and promote the commercialisation of intellectual property and medical products from NHS Trust in East Anglia.

Insight

View all Firm insight

Would you like to hear more from us?

Visit our subscriptions page to tell us a bit more about what you’re interested in so we can send you relevant news.

Sign up